Warner Chilcott (WCRX) Announces FDA Aproval of RYX Delayed-Release 150 mg Tablets
More News related to WCRX
- Warner Chilcott to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
- Roth Capital Downgrades Warner Chilcott (WCRX) to Hold
- Dutton Associates Announces Investment Opinion: NexMed Strong Speculative Buy Rating Maintained By Dutton Associates
- Warner Chilcott (WCRX) Tops Q2 View; Guides FY08
- Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2008 and Updates 2008 Full Year Guidance
More News related to FDA
- BioCryst Pharma (BCRX) Reports Results From BCX-4208 Phase IIa Trial in Subjects With Psoriasis
- Celgene (CELG) Granted FDA Fast Track Designation for Amrubicin
- GTC Biotherapeutics (GTCB) Granted Priority Review from the FDA
- EPIX Pharmaceuticals (EPIX) To Regain Full Worldwide Commercial Rights For Vasovist(R)
Warner Chilcott Limited (Nasdaq: WCRX) announced today that the FDA has approved a 150 mg strength of DORYX Delayed-Release Tablets.
DORYX Delayed-Release Tablets are a tetracycline-class oral antibiotic indicated for adjunctive treatment of severe acne.
Related Categories
FDAStocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
